Novo Nordisk's Older Weight Loss Drug May Slow Cognitive Decline in Alzheimer's Patients, Small Study Shows Brain-Protecting Benefits
Novo Nordisk's Older Weight Loss Drug May Slow Cognitive Decline in Alzheimer's Patients, Small Study Shows Brain-Protecting Benefits
GLP-1 receptor agonists mimic the natural hormone glucagon-like peptide and help manage diabetes, promote weight loss, and reduce heart disease, stroke, and kidney disease risks.A Phase 2b clinical trial presented at the Alzheimer's Association International Conference (AAIC) 2024 reveals that Novo Nordisk A/S's (NYSE:NVO) older generation GLP-1 drug, liraglutide, may slow cognitive decline by protecting the brain.
2024年在阿爾茨海默病國際協會年會上報道的20億期三期臨床試驗表明，諾和諾德（紐交所代碼：NVO）的老一代GLP-1藥物利拉魯肽可以通過保護大腦減緩認知衰退。
Related: Novo Nordisk's Ozempic Reduces Smoking-Related Health Interventions In Diabetic Patients, Study Finds.
相關新聞：諾和諾德的奧塞米匹（Ozempic）可以減少糖尿病病人吸菸相關的健康干預措施。
GLP-1 (Glucagon-Like Peptide-1) drugs are a class of medications primarily used to treat type 2 diabetes and, in some cases, obesity.
GLP-1（胰高糖素樣肽-1）藥物是一類主要用於治療2型糖尿病，以及在某些情況下用於治療肥胖症的藥物。
GLP-1 receptor agonists mimic the natural hormone glucagon-like peptide and help manage diabetes, promote weight loss, and reduce heart disease, stroke, and kidney disease risks.
GLP-1受體激動劑模擬天然荷爾蒙胰高糖素樣肽，有助於管理糖尿病、促進體重減輕，並降低心臟病、中風和腎病的風險。
Animal studies indicate these drugs may also have neuroprotective effects, reducing early forms of amyloid and normalizing brain glucose processing.
動物研究表明，這些藥物也可能具有神經保護作用，減少澱粉樣蛋白的早期形式並正常化大腦葡萄糖處理。
The study included 204 patients with mild Alzheimer's across 24 UK clinics. Participants received up to 1.8 mg of liraglutide or a daily placebo for a year.
研究包括來自24家英國診所的204名輕度阿爾茨海默病患者，參與者每天接受1.8毫克利拉魯肽或每天一次的安慰劑治療一年。
The primary endpoint, change in cerebral glucose metabolic rate (an assessment of brain function), was not met. However, significant benefits were observed in secondary endpoints like clinical and cognitive measures and brain volume changes.
主要終點——大腦葡萄糖代謝率的變化（大腦功能的一項評估）未達標。但在臨床和認知評估以及大腦體積變化等二級終點上觀察到顯著的益處。
Those on liraglutide experienced almost 50% less brain volume loss in critical regions such as the frontal, temporal, and parietal lobes.
那些服用利拉魯肽的人在關鍵區域，如額葉、顳葉和枕葉，腦部體積減少量幾乎減少了50％。
Cognitive testing before and after treatment showed an 18% slower decline in cognitive function among those on liraglutide compared to the placebo group.
治療前後的認知功能測試顯示，在利拉魯肽組中，認知功能的下降速度比安慰劑組慢18％。
Cognitive function was measured using a composite score from 18 different tests. The study also reported gastrointestinal issues, such as nausea, as the most common side effects, but serious side effects were relatively rare.
認知功能是使用18個不同測試的綜合得分來衡量的。該研究還報告了胃腸問題（如噁心）作爲最常見的副作用，但嚴重副作用相對較少。
Further research is warranted, but current late-stage trials of GLP-1 analogs, like the EVOKE Plus trial of semaglutide, are well-positioned to explore these findings further.
有待進一步研究，但目前的GLP-1類似物後期試驗（例如塞格露肽（semaglutide）的EVOKE Plus試驗）已經有了很好的探索這些發現的位置。
Reuters noted that its two trials began in 2021 and results are expected in 2025.
路透社指出，其兩次試驗始於2021年，結果預計將於2025年發佈。
Liraglutide, marketed as Saxenda for weight loss and Victoza for diabetes, has already been approved by the FDA.
利拉魯肽作爲用於減輕體重的Saxenda和治療糖尿病的Victoza已經獲得FDA批准。
Price Action: NVO stock is up 0.50% at $128.69 at the last check on Tuesday.
價格走勢：NVO股票在週二的最後一次查詢時上漲0.50％，爲128.69美元。
- Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off.
- 貝克與迪金森（Becton Dickinson）分拆後，胰島素裝置製造商Embecta考慮出售，股價下跌70％。
Photo via Shutterstock
圖片來自shutterstock。
